ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Novartis Presents Positive Results from JUNIPERA Study Supporting Cosentyx as a Treatment in a JIA Population
June 04, 2021Novartis, a leader in rheumatology and immuno-dermatology, announced 2-year positive results from the Phase III JUNIPERA study, demonstrating that Cosentyx® (secukinumab) significantly delayed time to flare vs placebo (P<.001) in pediatric patients ...
Pharma Sources Insight January 2025
